Особенности гуморального ответа у пациентов с COVID-19
DOI: https://doi.org/10.29296/25877305-2021-12-01
Номер журнала:
12
Год издания:
2021
В статье представлен краткий обзор накопленных данных по гуморальному (ГО) и T-клеточному ответу в
отношении вируса SARS-CoV-2 у пациентов с COVID-19. Дана характеристика антительного ответа, нейтрализующей
способности иммуноглобулина G к рецептор-связывающему домену (receptor binding domain – RBD), срокам
элиминации антител, авидности. Показано, что основной мишенью для выработки нейтрализующих антител является
RBD. Анализ и дальнейшее изучение детерминант SARS-CoV-2, ГО у пациентов с COVID-19 позволят разработать
более совершенные методы диагностики.
Ключевые слова:
инфекционные заболевания
противовирусный иммунитет
антитела при COVID-19
нейтрализующие антитела
сроки иммунного ответа
антитела к S-белку
RBD-домену
N-белку
Для цитирования
Л.В. Генералова, О.А. Бургасова, В.А. Гущин, Л.В. Колобухина, В.В. Бакалин, В.Б. Тетова, М.А. Одноралов, Е.А. Генералов Особенности гуморального ответа у пациентов с COVID-19
. Врач, 2021; (12): 5-11 https://doi.org/10.29296/25877305-2021-12-01Список литературы:
- Russell B., Moss C., George G. et al. Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence. Ecancermedicalscience. 2020; 14: 1022. DOI: 10.3332/ecancer.2020.1022
- Козлов В.А., Савченко А.А., Кудрявцев И.В. и др. Клиническая иммунология. Красноярск: Поликор, 2020; 386 с. [Kozlov V.A., Savchenko A.A., Kudryavtsev I.V. et al. Clinical immunology. Krasnoyarsk: Polikor, 2020; 386 s. (in Russ.)]. DOI: 10.17513/np.438
- Haslbauer J., Matter M., Stalder A. et al. Histomorphological patterns of regional lymph nodes in COVID-19 lungs. Pathologe. 2021; 42 (1): 89–97. DOI: 10.1007/s00292-021-00945-6
- Moon C. Fighting COVID-19 exhausts T cells. Nat Rev Immunol. 2020; 20: 277. DOI: 10.1038/s41577-020-0304-7
- Shi Y., Wang Y., Shao C. et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020; 27: 1451–4. DOI: 10.1038/s41418-020-0530-3
- Guo L., Ren L., Yang S. et al. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis. 2020; 71 (15): 778–85. DOI: 10.1093/cid/ciaa310
- Гудима Г.О., Хаитов Р.М., Кудлай Д.А. и др. Молекулярно-иммунологические аспекты диагностики, профилактики и лечения коронавирусной инфекции. Иммунология. 2021; 42 (3): 198–210 [Gudima G.O., Khaitov R.M., Kudlay D.A. et al. Molecular immunological aspects of diagnostics, prevention and treatment of coronavirus infection. Immunologiya. 2021; 42 (3): 198-210 (in Russ.)]. DOI: 10.33029/0206-4952-2021-42-3-198-210
- Zhao J., Yuan Q., Wang H. et al. Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clin Infect Dis. 2020; 71 (16): 2021–34. DOI: 10.1093/cid/ciaa344
- Wu L.P., Wang N.C., Chang Y.H. et al. Duration of antibody responses after severe acute respiratory syndrome. Emerg Infect Dis. 2007; 13: 1562–4. DOI: 10.3201/eid1310.070576
- Qu J., Wu C., Li X. et al. Profile of immunoglobulin G and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020; 71 (16): 2255–8. DOI: 10.1093/cid/ciaa489
- Wolfel R., Corman V., Guggemos W. et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020; 581 (7809): 465–9. DOI: 10.1038/s41586-020-2196-x
- Dan J., Mateus J., Kato Y.et al. Immunological memory to SARS-CoV-2 assessed for greater than six months after infection. bioRxiv. 2020.11.15.383323. DOI: 10.1101/2020.11.15.383323
- Qu J., Wu C., Li X. et al. Profile of Immunoglobulin G and IgM Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020; 71 (16): 2255–8. DOI: 10.1093/cid/ciaa489
- Wölfel R., Corman M., Guggemos W. et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020; 581: 465–9. DOI: 10.1038/s41586-020-2196-x
- Denning D., Kilcoyne A., Ucer C. Non-infectious status indicated by detectable IgG antibody to SARS-CoV-2. Br Dent J. 2020; 229: 521–4. DOI: 10.1038/s41415-020-2228-9
- Addetia A., Crawford K.H.D., Dingens A. et al. Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate. J Clin Microbiol. 2020; 58 (11): e02107-20. DOI: 10.1128/JCM.02107-20
- Pray I., Gibbons-Burgener S., Rosenberg A. et al. COVID-19 outbreak at an overnight summer school retreat – Wisconsin, July-August 2020. MMWR Morb Mortal Wkly Rep. 2020; 69 (43): 1600–4. DOI: 10.15585/mmwr.mm6943a4
- Jeffery-Smith A., Iyanger N., Williams S. et al. Antibodies to SARS-CoV-2 protect against re-infection during outbreaks in care homes, September and October 2020. Euro Surveill. 2021; 26 (5): 2100092. DOI: 10.2807/1560-7917
- Li K., Huang B., Wu M. et al. Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19. Nat Commun. 2020; 11 (1): 6004. DOI: 10.1038/s41467-020-19943-y
- Haddad N., Nguyen D., Kuruvilla M. et al. Elevated SARS-CoV-2 Antibodies Distinguish Severe Disease in Early COVID-19 Infection. bioRxiv. 2020.12.04.410589. DOI: 10.1101/2020.12.04.410589
- Jiang S., Hillyar C., Du L. et al. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses. Trends Immunol. 2020; 41 (5): 355–9. DOI: 10.1016/j.it.2020.03.007
- Benner S., Patel E., Laeyendecker O. et al. SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors. J Infect Dis. 2020; 222 (12): 1974–84. DOI: 10.1093/infdis/jiaa581
- Valdez-Cruz N., Garcia-Hernández E., Espitia C. et al. Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment. Microb Cell Fact. 2021; 20 (1): 88. DOI: 10.1186/s12934-021-01576-5
- Chia W.N., Zhu F., Ong S.W.X. et al. Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. [published correction appears in Lancet Microbe. 2021; 2 (5): e179]. Lancet Microbe. 2021; 2 (6): e240–e249. DOI: 10.1016/S2666-5247(21)00025-2
- Kening L., Bin H., Min W. et al. Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19. Nat Commun. 2020; 11 (1): 6044. DOI: 10.1038/s41467-020-19943-y
- Jiang H., Li Y., Zhang H. et al. SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses. Nat Commun. 2020; 11 (1): 3581. DOI: 10.1038/s41467-020-17488-8
- Whitcombe A., McGregor R., Craigie A. et al. Comprehensive analysis of SARS-CoV-2 antibody dynamics in New Zealand. Clin Transl Immunol. 2021; 10 (3): e1261. DOI: 10.1002/cti2.1261
- Guo L., Ren L., Yang S. et al. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Clin Infect Dis. 2020; 71 (15): 7778–85. DOI: 10.1093/cid/ciaa310
- Kohmer N., Westhaus S., Rühl C. et al. Clinical performance of different SARS-CoV-2 IgG antibody tests. J Med Virol. 2020; 92 (10): 2243–7. DOI: 10.1002/jmv.26145
- Li G., Chen X., Xu A. Profile of specific antibodies to the SARS-associated coronavirus. N Engl J Med. 2003; 349 (5): 508–9. DOI: 10.1056/NEJM200307313490520
- Qu J., Wu C., Li X. et al. Profile of IgG and IgM antibodies against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020; 27: ciaa489. DOI: 10.1093/cid/ciaa489
- Deeks J., Dinnes J., Takwoingi Y. et al. Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev. 2020; 6 (6): CD013652. DOI: 10.1002/14651858.CD013652
- Long Q., Tang X., Shi Q. et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020; 26: 1200–4 DOI: 10.1038/s41591-020-0965-6
- Lei Q., Li Y., Hou H. et al. Antibody dynamics to SARS-CoV-2 in asymptomatic COVID-19 infections. Allergy. 2021; 76 (2): 551–61. DOI: 10.1111/all.14622
- Chia W., Zhu F., Ong S. et al. Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. [published correction appears in Lancet Microbe. 2021; 2 (5): e179]. Lancet Microbe. 2021; 2 (6): e240–e249. DOI: 10.1016/S2666-5247(21)00025-2
- Wang C., Li W., Drabek D. et al.A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun. 2020; 11 (1): 2251. DOI: 10.1038/s41467-020-16256-y